The Human Papilloma Virus is the major cause of cervical cancer. Viral infection initiates cervical intraepithelial neoplasia which progresses through several stages to cervical cancer.
radically decrease. Even so, it will take decades for vaccination to take effect on cervical cancer rates (1) .
Incidence rates for Hispanic women are higher than those for non-Hispanic women. Even though the mortality rate for African American women has declined more rapidly than the rate for White women, the African American mortality rate continues to be more than double that of Whites (2) . Cervical cancer strikes nearly half a million women each year worldwide, claiming a quarter of a million lives (3).
The U.S. Food and Drug Administration (FDA) has approved two vaccines that are effective in preventing infection with types 16 and 18, two "high-risk" HPVs that cause most (70 percent) cervical cancers, and types 6 and 11, which cause most (90 percent) genital warts (4) . 3,3'-diindolylmethane (DIM) effectively inhibits CIN lesions in women with cervical dysplasia (8) (9) (10) . This has also been demonstrated in the K14-HPV16 mouse model used in this study (11) (12) (13) . DIM is an acid condensation product of indole-3-carbinol (I3C). I3C is formed enzymatically from the indole glucobrassinin which is found in cruciferous vegetables and spices, When I3C contacts the acid environment of the stomach several acid condensation products are formed. DIM comprises at least 70% of these compounds. The conversion is also common in tissue culture studies. In studies that use I3C, the active biological agent is DIM. This has been reviewed previously (12) . DIM alters the Phase I metabolism of estradiol and does not increase C-16 hydroxylation. C-16 hydroxylation produces 16-hydroxyestrone, an endogenous carcinogen and a promoter of HPV 16 and 18 proliferation or lytic phase (14) (15) (16) (17) . DIM, by altering the directional pathway of estrogen metabolism, and through other non-estrogenic effects, suppresses viral oncogene expression. DIM also suppresses pathology in recurrent respiratory papillomatosis, an HPV caused disease state (14, 15) . The change in estrogen metabolism is important since both primary cervical cells and foreskin cells transformed by HPV16 alter estrogen metabolism toward 16-hydroxylation (18 Tiwari and co-workers (19) have demonstrated that the chemopreventive and antitumor effects of 13C (DIM) depend on the species and tissue type. They studied the mechanism of action of I3C in estrogen-responsive (MCF-7) and estrogen-nonresponsive (MDAMB-231) human breast cancer cell lines. I3C inhibited the growth of estrogen-responsive cell line MCF-7 but had little effect on estrogen-nonresponsive cell line MDA-MB-231. Specific C-2 hydroxylation of estrogen and induction of cytochrome P-4501A1 was enhanced in the MCF-7 but not in the MDA-MB-231 cells. Their conclusion was that the inhibitory effects of I3C may involve selective induction of estradiol metabolism and the related cytochrome P-450 system that may be limited to estrogen-sensitive cells.
DIM directly disrupts various stages in HPV proliferation in both the initiation and progression from cervical dysplasia to cervical cancer. It has been demonstrated that DIM specifically inhibits proliferation of viral transcripts E6 and E7 in CaSki cells (9, 17) . DIM can induce a G 1 cell cycle arrest in MCF-7 cells that is accompanied by inhibition of cyclin-dependent kinase expression (20) . DIM inhibits cell adhesion, spreading and invasion associated with the upregulation of PTEN (a tumor suppressor gene) and E-cadherin (a regulator of cell cell adhesion) in T-47-D human breast cancer cells (21) . Additionally, DIM prevents PTEN loss in vivo in the K14HPV16 transgenic mouse (22) . This mouse model is used in our research.
DIM also elevates several key cytokines in vivo: Interferon-Gamma (IFN-), granulocyte colony stimulating factor (G-CSF), Interleukin-12 (IL-12), and Interleukin-6 (IL-6). IFN- is responsible for overall immune response system (23, 24) .
We have shown a reduction in the severity of CIN and in some cases the complete reversal of cervical dysplasia in women taking DIM for 4 weeks. This may indicate that HPV16 viral oncogene expression is suppressed after continued DIM administration (8, 10 The long range goal of this research is to test the theory that that 3,3'-diindolylmethane (DIM) acts to augment the efficacy of preventive and therapeutic HPV vaccines. An additional benefit may be that vaccine administration after DIM suppression of viral oncogenes will allow virus like particles (VLP) antibodies to form and thus prevent re-infection from new HPV exposure.
Before the research using DIM with vaccines can begin, the most effective minimum dose of DIM needs to be determined. Here we present some of the results of a DIM dose response study. Histology of the cervical epithelium from each dose group is presented. Urinary DIM concentrations are assessed for the first time in this model.
Methods
This study employs a well known transgenic mouse model commonly used in studies involving cervical dysplasia and cervical cancer (11-13, 25, 26) . Cervical neoplasia and cancer are linked to persistent infection of "high-risk" HPV viral types, where E6 and E7 oncogenes have 
The internal standard was added and the sample was extracted with chloroform. Twenty microliters of dry pyridine and 80 µl of N,O-bis(trimethylsilyl) trifluoroacetamide catalyzed with 1% trimethyl-chlorosilane (Pierce Chemical, Rockford, IL) were added, and the sample was heated to 100°C for 1h. The sample was injected without further treatment. Gas Chromatography-Mass Spectrometry conditions were the same as those described by Sepkovic et al (10). Creatinine determinations were performed colorimetrically using an ELISA kit provided by Assay Designs (Ann Arbor, MI).
Statistical Methods
Treatment of cervical histology data-The outcome of interest is the incidence rate of mice that were CIN free at each dose level at 20 weeks. Since normal histology (CIN free rate) at the end of the study period is desirable, we collapsed the ordinal response into CIN free (normal) and CIN to yield a binary response.
To examine evidence of a dose response relationship, a Cochran-Armitage test (27,28) was conducted. Further, the minimum effective dose was determined using pair wise Fisher exact tests for comparisons of treated mice and 0 DIM dose groups. The realized raw pair wise test p-values, were adjusted for family wise error rate (FWER) by the step-down Hochberg procedure (28-31) before identifying the smallest DIM dose with an effect on CIN freedom (29) . All statistical testing was performed such that P-value<0.05% indicated statistical significance.
Treatment of urinary DIM data-
All data analysis in this study was performed using SAS version 9.2 (SAS Institute Inc, Cary, NC) (30, 31) .
Results
Food consumption and body weights were measured weekly throughout the experimental period. Over the twenty week study, no significant differences in body weight were observed between wild type controls and transgenic mice in any DIM dose group. There were also no significant differences when the transgenic dose groups were compared. All groups had dietary food consumption levels that were consistent with animal feeding recommendations for mice on custom purified diet (3-6g/animal/day) (32). There were no significant differences in food consumption within or between groups.
Histology-Each figure compares wild type and transgenic mouse cervical epithelia from the same dose group shown side by side. Figure 1 illustrates carcinoma in situ (NCIS) frequently found in transgenic mice that receive estradiol pellets without DIM administration (0ppm DIM transgenic). Commonly, cytological squamous cell progression and severe irregularity of the epithelial-stromal border are observed. In Figure 2 , the cervical epithelium of a transgenic mouse receiving 1000ppm in the diet is normal. Table 2 summarizes the histological comparison of the cervical transformation zone in each dose group. Results from the wild type mice that were assigned to the same dosing pattern as the transgenic mice are also presented. The endpoint in this analysis is the cervical histology examined at 20 weeks and the outcome of interest is the incidence rate of mice that were CIN free at each dose level.
To analyze the dose response, we first established whether or not there was a trend effect of the DIM dose on the binary response CIN free versus CIN. Based on the 128 transgenic mice that were randomly assigned to the control and five doses, this test indicated that there is significant positive linear trend (P<0.0001) such that as the DIM dose increased the proportion that were CIN free at 20 weeks also increased. With regard to the wild type mice the dose effect was not significant (P=0.5327).
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In transgenic mice, pair wise comparisons between the 5 dose levels and the 0 ppm DIM dose were performed to determine which doses were significantly from the control. There was no difference between the 0ppmDIM group and the 500ppm DIM group. At 1000ppm, there was a significant increase in normal mice (P=0.0123). This difference is reflected in the higher DIM dose groups.
The results show that DIM Dose of 500 ppm was not significantly different from the 0 ppm DIM (P=1.00) with respect to the rate of CIN free animals. Our analysis indicated that 1000 ppm of DIM was the smallest dose that reported a response significantly different from the control (P=0.0123), yielding the minimum effective dose for the study.
Notable was the fact that 21% of mice in the 0ppm DIM group and 5% on the 500ppm DIM groups had either NCIS or SCC. No cancers were reported at1000ppm DIM or higher.
With regard to the wild type mice the dose effect was not significant (P=0.5327), which means based on the 163 mice; there was no DIM dose effect on the CIN freedom at 20 weeks.
Urine DIM levels-The DIM concentrations normalized by creatinine (ng/mg) were measured and summarized as median values as shown in Figure 3 . There was a significant trend in this parameter (P<0.0001). Urine DIM concentrations increased significantly in a linear fashion with each DIM dose group in both transgenic and wild type mice (P<0.05).
Discussion-In this study we determine the minimum effective dose of DIM that prevents cervical dysplasia using a transgenic mouse model. At 1000ppm (DIM in food) significant numbers of mice with normal cervical epithelia were obtained after 20 weeks. NCIS and SCC were completely eliminated in the1000ppm DIM group compared to 21% of cancers in the Legend-Known concentrations of DIM were aliquoted in triplicate to urine in each group. The internal standard was added and each sample was extracted and derivitized. 
